XML 82 R59.htm IDEA: XBRL DOCUMENT
v3.24.3

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 29, 2024 | Oct. 01, 2023 | Sep. 29, 2024 | Oct. 01, 2023
Sales by segment of business |  |  |  |
Sales to customers | $ 22,471 | $ 21,351 | $ 66,301 | $ 63,764
Percent Change (as a percent) | 5.20% |  | 4.00% |
U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 12,909 | 11,996 | $ 37,098 | 34,435
Percent Change (as a percent) | 7.60% |  | 7.70% |
International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 9,562 | 9,355 | $ 29,203 | 29,329
Percent Change (as a percent) | 2.20% |  | (0.40%) |
Innovative Medicine |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 14,580 | 13,893 | $ 42,632 | 41,037
Percent Change (as a percent) | 4.90% |  | 3.90% |
Innovative Medicine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 8,871 | 8,249 | $ 24,993 | 23,090
Percent Change (as a percent) | 7.50% |  | 8.20% |
Innovative Medicine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 5,709 | 5,644 | $ 17,639 | 17,947
Percent Change (as a percent) | 1.20% |  | (1.70%) |
Innovative Medicine | Immunology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,621 | 4,849 | $ 13,590 | 13,457
Percent Change (as a percent) | (4.70%) |  | 1.00% |
Innovative Medicine | Immunology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,068 | 3,193 | $ 8,499 | 8,506
Percent Change (as a percent) | (3.90%) |  | (0.10%) |
Innovative Medicine | Immunology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,552 | 1,656 | $ 5,090 | 4,951
Percent Change (as a percent) | (6.20%) |  | 2.80% |
Innovative Medicine | Immunology | REMICADE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 419 | 461 | $ 1,246 | 1,410
Percent Change (as a percent) | (9.10%) |  | (11.60%) |
Innovative Medicine | Immunology | REMICADE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 281 | 296 | $ 778 | 849
Percent Change (as a percent) | (5.40%) |  | (8.50%) |
Innovative Medicine | Immunology | REMICADE | U.S. Exports |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 27 | 38 | $ 89 | 112
Percent Change (as a percent) | (28.90%) |  | (20.50%) |
Innovative Medicine | Immunology | REMICADE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 112 | 127 | $ 380 | 449
Percent Change (as a percent) | (11.50%) |  | (15.40%) |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 516 | 629 | $ 1,607 | 1,695
Percent Change (as a percent) | (18.00%) |  | (5.20%) |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 299 | 310 | $ 820 | 866
Percent Change (as a percent) | (3.70%) |  | (5.30%) |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 218 | 319 | $ 787 | 829
Percent Change (as a percent) | (31.80%) |  | (5.10%) |
Innovative Medicine | Immunology | STELARA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,676 | 2,864 | $ 8,012 | 8,105
Percent Change (as a percent) | (6.60%) |  | (1.20%) |
Innovative Medicine | Immunology | STELARA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,770 | 1,912 | $ 5,021 | 5,180
Percent Change (as a percent) | (7.50%) |  | (3.10%) |
Innovative Medicine | Immunology | STELARA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 906 | 951 | $ 2,991 | 2,925
Percent Change (as a percent) | (4.80%) |  | 2.20% |
Innovative Medicine | Immunology | TREMFYA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,007 | 891 | $ 2,721 | 2,237
Percent Change (as a percent) | 13.00% |  | 21.60% |
Innovative Medicine | Immunology | TREMFYA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 691 | 634 | $ 1,789 | 1,490
Percent Change (as a percent) | 9.10% |  | 20.10% |
Innovative Medicine | Immunology | TREMFYA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 316 | 258 | $ 932 | 747
Percent Change (as a percent) | 22.60% |  | 24.70% |
Innovative Medicine | Immunology | OTHER IMMUNOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1 | 2 | $ 3 | 9
Percent Change (as a percent) | (45.60%) |  | (66.80%) |
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1 | 2 | $ 3 | 9
Percent Change (as a percent) | (45.60%) |  | (66.80%) |
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
Innovative Medicine | Infectious Diseases |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 836 | 859 | $ 2,622 | 3,566
Percent Change (as a percent) | (2.70%) |  | (26.50%) |
Innovative Medicine | Infectious Diseases | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 365 | 360 | $ 1,023 | 1,147
Percent Change (as a percent) | 1.50% |  | (10.80%) |
Innovative Medicine | Infectious Diseases | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 471 | 500 | $ 1,599 | 2,420
Percent Change (as a percent) | (5.70%) |  | (33.90%) |
Innovative Medicine | Infectious Diseases | COVID-19 |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1 | 41 | $ 198 | 1,073
Percent Change (as a percent) | (97.70%) |  | (81.60%) |
Innovative Medicine | Infectious Diseases | COVID-19 | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
Innovative Medicine | Infectious Diseases | COVID-19 | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1 | 41 | $ 198 | 1,073
Percent Change (as a percent) | (97.70%) |  | (81.60%) |
Innovative Medicine | Infectious Diseases | EDURANT / rilpivirine |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 330 | 297 | $ 950 | 843
Percent Change (as a percent) | 11.50% |  | 12.70% |
Innovative Medicine | Infectious Diseases | EDURANT / rilpivirine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 8 | 9 | $ 24 | 26
Percent Change (as a percent) | (15.80%) |  | (10.00%) |
Innovative Medicine | Infectious Diseases | EDURANT / rilpivirine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 323 | 287 | $ 926 | 816
Percent Change (as a percent) | 12.30% |  | 13.50% |
Innovative Medicine | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 449 | 447 | $ 1,305 | 1,415
Percent Change (as a percent) | 0.60% |  | (7.80%) |
Innovative Medicine | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 355 | 345 | $ 990 | 1,105
Percent Change (as a percent) | 2.80% |  | (10.50%) |
Innovative Medicine | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 94 | 102 | $ 315 | 310
Percent Change (as a percent) | (6.90%) |  | 1.80% |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 55 | 74 | $ 169 | 235
Percent Change (as a percent) | (25.40%) |  | (28.00%) |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3 | 5 | $ 10 | 15
Percent Change (as a percent) | (52.20%) |  | (37.70%) |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 53 | 69 | $ 160 | 220
Percent Change (as a percent) | (23.20%) |  | (27.40%) |
Innovative Medicine | Neuroscience |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,755 | 1,742 | $ 5,340 | 5,339
Percent Change (as a percent) | 0.80% |  | 0.00% |
Innovative Medicine | Neuroscience | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,094 | 1,036 | $ 3,250 | 3,043
Percent Change (as a percent) | 5.60% |  | 6.80% |
Innovative Medicine | Neuroscience | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 662 | 706 | $ 2,090 | 2,296
Percent Change (as a percent) | (6.20%) |  | (8.90%) |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 142 | 189 | $ 482 | 603
Percent Change (as a percent) | (24.80%) |  | (20.00%) |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 26 | 57 | $ 101 | 191
Percent Change (as a percent) | (55.00%) |  | (47.50%) |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 117 | 133 | $ 382 | 412
Percent Change (as a percent) | (11.90%) |  | (7.30%) |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,049 | 1,029 | $ 3,159 | 3,104
Percent Change (as a percent) | 1.90% |  | 1.80% |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 780 | 730 | $ 2,329 | 2,164
Percent Change (as a percent) | 6.80% |  | 7.60% |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 269 | 299 | $ 830 | 940
Percent Change (as a percent) | (10.10%) |  | (11.70%) |
Innovative Medicine | Neuroscience | SPRAVATO |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 284 | 183 | $ 780 | 483
Percent Change (as a percent) | 54.90% |  | 61.50% |
Innovative Medicine | Neuroscience | SPRAVATO | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 243 | 154 | $ 660 | 409
Percent Change (as a percent) | 56.80% |  | 61.20% |
Innovative Medicine | Neuroscience | SPRAVATO | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 42 | 29 | $ 120 | 74
Percent Change (as a percent) | 44.60% |  | 62.90% |
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 281 | 340 | $ 920 | 1,149
Percent Change (as a percent) | (17.40%) |  | (19.90%) |
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 46 | 94 | $ 161 | 278
Percent Change (as a percent) | (51.40%) |  | (42.10%) |
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 235 | 245 | $ 759 | 870
Percent Change (as a percent) | (4.40%) |  | (12.80%) |
Innovative Medicine | Oncology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 5,380 | 4,533 | $ 15,284 | 13,043
Percent Change (as a percent) | 18.70% |  | 17.20% |
Innovative Medicine | Oncology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,816 | 2,219 | $ 7,835 | 6,177
Percent Change (as a percent) | 26.90% |  | 26.80% |
Innovative Medicine | Oncology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,565 | 2,313 | $ 7,450 | 6,865
Percent Change (as a percent) | 10.90% |  | 8.50% |
Innovative Medicine | Oncology | CARVYKTI |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 286 | 152 | $ 629 | 341
Percent Change (as a percent) | 87.70% |  | 84.30% |
Innovative Medicine | Oncology | CARVYKTI | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 258 | 140 | $ 565 | 324
Percent Change (as a percent) | 84.90% |  | 74.60% |
Innovative Medicine | Oncology | CARVYKTI | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 27 | 12 | $ 63 | 17
Innovative Medicine | Oncology | DARZALEX |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,016 | 2,499 | $ 8,586 | 7,194
Percent Change (as a percent) | 20.70% |  | 19.30% |
Innovative Medicine | Oncology | DARZALEX | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,684 | 1,369 | $ 4,789 | 3,882
Percent Change (as a percent) | 23.00% |  | 23.40% |
Innovative Medicine | Oncology | DARZALEX | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,332 | 1,130 | $ 3,797 | 3,312
Percent Change (as a percent) | 17.90% |  | 14.60% |
Innovative Medicine | Oncology | ERLEADA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 790 | 631 | $ 2,215 | 1,740
Percent Change (as a percent) | 25.40% |  | 27.30% |
Innovative Medicine | Oncology | ERLEADA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 337 | 288 | $ 940 | 778
Percent Change (as a percent) | 17.10% |  | 20.80% |
Innovative Medicine | Oncology | ERLEADA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 453 | 342 | $ 1,275 | 961
Percent Change (as a percent) | 32.40% |  | 32.60% |
Innovative Medicine | Oncology | IMBRUVICA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 753 | 808 | $ 2,307 | 2,476
Percent Change (as a percent) | (6.80%) |  | (6.80%) |
Innovative Medicine | Oncology | IMBRUVICA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 259 | 264 | $ 770 | 796
Percent Change (as a percent) | (1.90%) |  | (3.20%) |
Innovative Medicine | Oncology | IMBRUVICA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 494 | 545 | $ 1,537 | 1,681
Percent Change (as a percent) | (9.20%) |  | (8.50%) |
Innovative Medicine | Oncology | Tecvayli |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 135 | 112 | $ 403 | 269
Percent Change (as a percent) | 20.60% |  | 49.60% |
Innovative Medicine | Oncology | Tecvayli | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 105 | 93 | $ 310 | 232
Percent Change (as a percent) | 13.50% |  | 34.00% |
Innovative Medicine | Oncology | Tecvayli | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 30 | 19 | $ 93 | 37
Percent Change (as a percent) | 54.20% |  |  |
Innovative Medicine | Oncology | ZYTIGA / abiraterone acetate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 150 | 214 | $ 496 | 686
Percent Change (as a percent) | (30.00%) |  | (27.80%) |
Innovative Medicine | Oncology | ZYTIGA / abiraterone acetate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 5 | 16 | $ 25 | 41
Percent Change (as a percent) | (66.00%) |  | (38.00%) |
Innovative Medicine | Oncology | ZYTIGA / abiraterone acetate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 144 | 199 | $ 470 | 646
Percent Change (as a percent) | (27.10%) |  | (27.10%) |
Innovative Medicine | Oncology | OTHER ONCOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 250 | 117 | $ 649 | 336
Percent Change (as a percent) |  |  | 93.40% |
Innovative Medicine | Oncology | OTHER ONCOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 168 | 50 | $ 435 | 125
Innovative Medicine | Oncology | OTHER ONCOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 83 | 67 | $ 214 | 211
Percent Change (as a percent) | 24.80% |  | 2.00% |
Innovative Medicine | Pulmonary Hypertension |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,102 | 954 | $ 3,190 | 2,798
Percent Change (as a percent) | 15.60% |  | 14.00% |
Innovative Medicine | Pulmonary Hypertension | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 815 | 680 | $ 2,324 | 1,964
Percent Change (as a percent) | 20.00% |  | 18.40% |
Innovative Medicine | Pulmonary Hypertension | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 287 | 274 | $ 866 | 835
Percent Change (as a percent) | 4.50% |  | 3.70% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 571 | 490 | $ 1,639 | 1,437
Percent Change (as a percent) | 16.80% |  | 14.10% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 406 | 323 | $ 1,135 | 924
Percent Change (as a percent) | 25.40% |  | 22.80% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 165 | 166 | $ 504 | 512
Percent Change (as a percent) | (0.20%) |  | (1.60%) |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 458 | 402 | $ 1,352 | 1,163
Percent Change (as a percent) | 14.20% |  | 16.30% |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 379 | 336 | $ 1,120 | 978
Percent Change (as a percent) | 12.70% |  | 14.50% |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 80 | 66 | $ 232 | 185
Percent Change (as a percent) | 21.80% |  | 25.50% |
Innovative Medicine | Pulmonary Hypertension | Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 72 | 63 | $ 199 | 199
Percent Change (as a percent) | 15.00% |  | 0.30% |
Innovative Medicine | Pulmonary Hypertension | Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 32 | 20 | $ 70 | 61
Percent Change (as a percent) | 54.00% |  | 14.00% |
Innovative Medicine | Pulmonary Hypertension | Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 40 | 42 | $ 129 | 137
Percent Change (as a percent) | (3.90%) |  | (5.80%) |
Innovative Medicine | Cardiovascular / Metabolism / Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 884 | 957 | $ 2,605 | 2,834
Percent Change (as a percent) | (7.60%) |  | (8.10%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 713 | 763 | $ 2,061 | 2,254
Percent Change (as a percent) | (6.50%) |  | (8.50%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 170 | 194 | $ 543 | 580
Percent Change (as a percent) | (11.90%) |  | (6.40%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 292 | 332 | $ 908 | 994
Percent Change (as a percent) | (12.00%) |  | (8.70%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 121 | 139 | $ 364 | 414
Percent Change (as a percent) | (12.20%) |  | (11.90%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 170 | 194 | $ 543 | 580
Percent Change (as a percent) | (11.90%) |  | (6.40%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 592 | 625 | $ 1,697 | 1,840
Percent Change (as a percent) | (5.20%) |  | (7.80%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 592 | 625 | $ 1,697 | 1,840
Percent Change (as a percent) | (5.20%) |  | (7.80%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
MEDTECH |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 7,891 | 7,458 | $ 23,669 | 22,727
Percent Change (as a percent) | 5.80% |  | 4.10% |
MEDTECH | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,038 | 3,747 | $ 12,105 | 11,345
Percent Change (as a percent) | 7.80% |  | 6.70% |
MEDTECH | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,853 | 3,711 | $ 11,564 | 11,382
Percent Change (as a percent) | 3.90% |  | 1.60% |
MEDTECH | Cardiovascular |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,966 | 1,558 | $ 5,645 | 4,681
Percent Change (as a percent) | 26.20% |  | 20.60% |
MEDTECH | Cardiovascular | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,148 | 891 | $ 3,292 | 2,662
Percent Change (as a percent) | 28.60% |  | 23.60% |
MEDTECH | Cardiovascular | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 819 | 667 | $ 2,353 | 2,019
Percent Change (as a percent) | 22.80% |  | 16.50% |
MEDTECH | ELECTROPHYSIOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,279 | 1,161 | $ 3,946 | 3,449
Percent Change (as a percent) | 10.20% |  | 14.40% |
MEDTECH | ELECTROPHYSIOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 660 | 611 | $ 2,057 | 1,791
Percent Change (as a percent) | 7.90% |  | 14.80% |
MEDTECH | ELECTROPHYSIOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 619 | 549 | $ 1,889 | 1,658
Percent Change (as a percent) | 12.70% |  | 14.00% |
MEDTECH | ABIOMED |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 362 | 311 | $ 1,112 | 966
Percent Change (as a percent) | 16.30% |  | 15.10% |
MEDTECH | ABIOMED | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 293 | 254 | $ 905 | 790
Percent Change (as a percent) | 15.40% |  | 14.50% |
MEDTECH | ABIOMED | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 68 | 57 | $ 207 | 176
Percent Change (as a percent) | 20.10% |  | 17.70% |
MEDTECH | Shockwave |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 229 | 0 | $ 306 | 0
MEDTECH | Shockwave | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 163 | 0 | 240 | 0
MEDTECH | Shockwave | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 66 | 0 | 66 | 0
MEDTECH | Other Cardiovascular |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 96 | 87 | $ 281 | 267
Percent Change (as a percent) | 10.40% |  | 5.30% |
MEDTECH | Other Cardiovascular | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 30 | 26 | $ 89 | 81
Percent Change (as a percent) | 16.70% |  | 10.60% |
MEDTECH | Other Cardiovascular | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 66 | 61 | $ 192 | 186
Percent Change (as a percent) | 7.70% |  | 3.00% |
MEDTECH | Orthopaedics |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,191 | 2,164 | $ 6,843 | 6,674
Percent Change (as a percent) | 1.20% |  | 2.50% |
MEDTECH | Orthopaedics | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,359 | 1,349 | $ 4,229 | 4,100
Percent Change (as a percent) | 0.70% |  | 3.20% |
MEDTECH | Orthopaedics | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 832 | 815 | $ 2,614 | 2,574
Percent Change (as a percent) | 2.00% |  | 1.50% |
MEDTECH | Orthopaedics | HIPS |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 381 | 375 | $ 1,220 | 1,162
Percent Change (as a percent) | 1.70% |  | 5.00% |
MEDTECH | Orthopaedics | HIPS | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 250 | 239 | $ 785 | 730
Percent Change (as a percent) | 4.80% |  | 7.50% |
MEDTECH | Orthopaedics | HIPS | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 131 | 136 | $ 435 | 432
Percent Change (as a percent) | (3.60%) |  | 0.60% |
MEDTECH | Orthopaedics | KNEES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 352 | 338 | $ 1,147 | 1,069
Percent Change (as a percent) | 4.00% |  | 7.20% |
MEDTECH | Orthopaedics | KNEES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 212 | 207 | $ 684 | 654
Percent Change (as a percent) | 2.20% |  | 4.50% |
MEDTECH | Orthopaedics | KNEES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 140 | 131 | $ 463 | 415
Percent Change (as a percent) | 6.90% |  | 11.50% |
MEDTECH | Orthopaedics | TRAUMA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 761 | 742 | $ 2,285 | 2,238
Percent Change (as a percent) | 2.60% |  | 2.10% |
MEDTECH | Orthopaedics | TRAUMA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 497 | 488 | $ 1,499 | 1,462
Percent Change (as a percent) | 1.80% |  | 2.50% |
MEDTECH | Orthopaedics | TRAUMA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 265 | 253 | $ 786 | 775
Percent Change (as a percent) | 4.20% |  | 1.40% |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 696 | 710 | $ 2,191 | 2,205
Percent Change (as a percent) | (1.90%) |  | (0.60%) |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 400 | 415 | $ 1,262 | 1,254
Percent Change (as a percent) | (3.60%) |  | 0.60% |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 296 | 295 | $ 930 | 952
Percent Change (as a percent) | 0.40% |  | (2.30%) |
MEDTECH | Surgery |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,434 | 2,479 | $ 7,338 | 7,507
Percent Change (as a percent) | (1.80%) |  | (2.20%) |
MEDTECH | Surgery | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 983 | 994 | $ 2,965 | 2,984
Percent Change (as a percent) | (1.10%) |  | (0.60%) |
MEDTECH | Surgery | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,451 | 1,483 | $ 4,373 | 4,522
Percent Change (as a percent) | (2.20%) |  | (3.30%) |
MEDTECH | Surgery | ADVANCED |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,109 | 1,164 | $ 3,337 | 3,504
Percent Change (as a percent) | (4.70%) |  | (4.80%) |
MEDTECH | Surgery | ADVANCED | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 448 | 455 | $ 1,360 | 1,365
Percent Change (as a percent) | (1.40%) |  | (0.40%) |
MEDTECH | Surgery | ADVANCED | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 661 | 709 | $ 1,977 | 2,139
Percent Change (as a percent) | (6.80%) |  | (7.60%) |
MEDTECH | Surgery | GENERAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,325 | 1,314 | $ 4,001 | 4,002
Percent Change (as a percent) | 0.80% |  | 0.00% |
MEDTECH | Surgery | GENERAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 535 | 540 | $ 1,605 | 1,619
Percent Change (as a percent) | (0.90%) |  | (0.90%) |
MEDTECH | Surgery | GENERAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 791 | 775 | $ 2,397 | 2,383
Percent Change (as a percent) | 2.10% |  | 0.60% |
MEDTECH | Vision |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,300 | 1,256 | $ 3,843 | 3,864
Percent Change (as a percent) | 3.50% |  | (0.50%) |
MEDTECH | Vision | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 549 | 512 | $ 1,619 | 1,599
Percent Change (as a percent) | 7.20% |  | 1.30% |
MEDTECH | Vision | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 751 | 744 | $ 2,224 | 2,265
Percent Change (as a percent) | 0.90% |  | (1.80%) |
MEDTECH | Vision | CONTACT LENSES / OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 968 | 928 | $ 2,796 | 2,820
Percent Change (as a percent) | 4.20% |  | (0.90%) |
MEDTECH | Vision | CONTACT LENSES / OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 441 | 399 | $ 1,288 | 1,252
Percent Change (as a percent) | 10.20% |  | 2.80% |
MEDTECH | Vision | CONTACT LENSES / OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 527 | 529 | $ 1,508 | 1,568
Percent Change (as a percent) | (0.30%) |  | (3.80%) |
MEDTECH | Vision | SURGICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 333 | 328 | $ 1,048 | 1,044
Percent Change (as a percent) | 1.30% |  | 0.30% |
MEDTECH | Vision | SURGICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 108 | 112 | $ 331 | 346
Percent Change (as a percent) | (3.60%) |  | (4.40%) |
MEDTECH | Vision | SURGICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 225 | $ 216 | $ 717 | $ 698
Percent Change (as a percent) | 3.90% |  | 2.70% |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_COVID19Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPRAVATOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CARVYKTIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ERLEADAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TecvayliMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ElectrophysiologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_AbiomedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ShockwaveMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OtherCardiovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |